ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$87.49
−0.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | 50.8M |
| Gross Profit | — | — | — | — | (50.8M) |
| Operating Expenses | |||||
| R&D Expense | 180.7M | 177.8M | 146.5M | 103.2M | 48.3M |
| SG&A Expense | 72.5M | 72.9M | 38.9M | 28.8M | 7.5M |
| General & Admin Expense | 72.2M | 72.6M | 38.0M | 28.1M | 7.5M |
| Selling & Marketing Expense | 322.0K | 224.0K | 932.0K | 709.0K | — |
| Other Expenses | 124.2M | (4.6M) | (12.4M) | (4.6M) | (41.7M) |
| Total Operating Expenses | 377.4M | 246.1M | 173.0M | 127.4M | 14.1M |
| Cost and Expenses | 377.4M | 246.1M | 173.0M | 127.4M | 64.8M |
| Operating Income (EBIT) | (377.4M) | (246.1M) | (173.0M) | (127.4M) | (64.8M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 5.8M | 9.0M | 2.8M | — |
| Interest Expense | 24.1M | 28.5M | 12.4M | 13.8M | 6.9M |
| Net Interest Income | (20.6M) | (22.7M) | (3.5M) | (11.1M) | (6.9M) |
| Other Non-Op Income/Expense | (128.8M) | (84.2M) | (3.3M) | (20.4M) | 4.1M |
| Non-Operating Income (excl Interest) | 95.0M | 55.7M | (9.2M) | 6.5M | (11.0M) |
| EBT (Pre-Tax Income) | (506.1M) | (330.3M) | (176.2M) | (147.7M) | (60.7M) |
| Income Tax Expense | (228.0K) | 5.8M | — | — | — |
| Bottom Line | |||||
| Net Income | (505.9M) | (336.1M) | (176.2M) | (147.7M) | (60.7M) |
| Earnings from Cont. Ops | (505.9M) | (336.1M) | (176.2M) | (147.7M) | (60.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (505.9M) | (336.1M) | (176.2M) | (147.7M) | (60.7M) |
| Per Share | |||||
| Basic EPS | ($6.66) | ($4.65) | ($2.80) | ($3.43) | ($3.18) |
| Diluted EPS | ($6.66) | ($4.65) | ($2.80) | ($3.43) | ($3.18) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 79.6M | 69.5M | 63.0M | 43.1M | 19.1M |
| Diluted Shares Outstanding | 79.6M | 69.5M | 63.0M | 43.1M | 19.1M |
| Profitability Metrics | |||||
| EBITDA | (471.1M) | (300.7M) | (162.7M) | (133.2M) | (53.3M) |
| D&A | 1.3M | 1.1M | 1.1M | 707.0K | 485.0K |
| EBIT | (472.4M) | (301.8M) | (163.8M) | (133.9M) | (53.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026